Teleconferência de Resultados do 2º Trimestre de 2026 da HeartBeam (BEAT): Submissão ao FDA, Menor Queima de Caixa e Lançamento Comercial
A teleconferência de resultados do 2º trimestre de 2026 da HeartBeam abordou um prejuízo líquido de US$ 5 milhões, uma menor queima de caixa, avanços junto à FDA e o início do lançamento comercial em quatro mercados dos EUA.
HeartBeam, Inc. is a cardiac technology company. The Company focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. It is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. It is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.